| | Parameter | Post-TURP
Top-down HoLEP
n = 68 | Nonrecurrent
Top-down HoLEP
n = 201 | value |
| | Outcomes at 1 month | | Number of patients, n (%) | 65/68 (95.6) | 192/201 (95.5) | — | | IPSS, median (range) | 6 (0–25) | 7 (0–25) | 0.24 | | QoL, median (range) | 1 (0–6) | 2 (0–6) | 0.11 | | Qmax, median (range), mL/s | 24.1 (5.3–65) | 24 (5.8–73.3) | 0.90 | | PVR, median (range), mL | 41 (0–400) | 46.5 (0–393) | 0.70 | | Stress incontinence, n (%) | 5 (7.3) | 11 (5.5) | 0.59 |
| | Outcomes at 3 months | | Number of patients, n (%) | 63/68 (92.6) | 183/201 (91) | — | | IPSS, median (range) | 5 (0–23) | 4 (0.27) | 0.73 | | QoL, median (range) | 1 (0–6) | 1 (0–6) | 0.08 | | Qmax, median (range), mL/s | 21.5 (3–47.3) | 21.7 (7.8–54.2) | 0.97 | | PVR, median (range), mL | 56 (0–225) | 44 (0–400) | 0.88 | | Stress incontinence, n (%) | 2 (2.9) | 3 (1.5) | 0.44 | | % PSA reduction, median (range) | 88.5 (−67.1–97.9) | 87.4 (−27.3–98.9) | 0.63 |
| | Outcomes at 6 months | | Number of patients, n (%) | 61/68 (89.7) | 171/201 (85.1) | — | | IPSS, median (range) | 3.5 (0–17) | 4 (0–23) | 0.27 | | QoL, median (range) | 0.5 (0–4) | 1 (0–6) | 0.68 | | Qmax, median (range), mL/s | 24.8 (13.4–47.8) | 23.7 (6.9–69) | 0.50 | | PVR, median (range), mL | 38 (0–285) | 47 (0–480) | 0.80 | | Stress incontinence, n (%) | 1 (1.5) | 2 (0.9) | 0.75 |
| | Outcomes at 12 months | | Number of patients, n (%) | 59/68 (86.8) | 168/201 (83.6) | — | | IPSS, median (range) | 2.5 (0–17) | 3 (0–17) | 0.65 | | QoL, median (range) | 0.5 (0–3) | 0 (0–4) | 0.54 | | Qmax, median (range), mL/s | 28.3 (9.6–51.4) | 24.3 (5.2–65.4) | 0.82 | | PVR, median (range), mL | 28.5 (0–185) | 36 (0–790) | 0.63 | | Stress incontinence, n (%) | 1 (1.5) | 0 (0) | 0.09 |
|
|
n, number; IPSS, International Prostate Symptom Score; QoL, quality of life; Qmax, maximum flow rate; PVR, postvoid residual; PSA, prostate-specific antigen.
|
